Caltech's BrainCAB: A Glaucoma Drug Repurposed as Molecular Shuttle Across Blood-Brain Barrier

The blood-brain barrier is one of nature's most effective security systems. It stands guard at the boundary between the bloodstream and the brain, filtering out toxins and pathogens with ruthless efficiency. But that same barrier has become one of medicine's most stubborn problems: it blocks not just harmful substances, but also the drugs that could treat brain diseases. A patient with a treatable neurological condition might have a medicine that works in theory, only to find it cannot penetrate the brain's protective wall. Caltech researchers have now found an unexpected way around this impasse, using a drug originally designed to treat glaucoma as a molecular ferry service.

The challenge has haunted neuroscience for more than a decade. Existing solutions exist, but each carries its own burden. Brain surgery is invasive. Focused ultrasound is limited in scope. Engineered viruses can cross the barrier, but they struggle with larger cargo—antibodies, proteins, RNA medicines—the very molecules that might treat the most serious neurological conditions. In 2023, Caltech scientists made a discovery that would reshape their approach. They found that carbonic anhydrase IV, an enzyme sitting on the surface of blood vessel cells in the brain, acts as a natural receptor. Certain engineered viruses could exploit this receptor to slip across the barrier through a process called receptor-mediated transcytosis. The question that followed was simple and elegant: could they use the same biological pathway without the virus?

The answer came from an unlikely source. Researcher Xiaozhe Ding used structural modeling to examine brinzolamide, a common prescription eye drop for glaucoma. The molecule's shape suggested it could bind to carbonic anhydrase IV at a site similar to where certain viruses attach. That observation sparked collaboration between Viviana Gradinaru's neuroscience lab and Sarah Reisman's chemistry lab. They set out to modify brinzolamide so it could maintain its grip on the enzyme while also carrying therapeutic cargo. As Reisman noted, chemical synthesis is modular—you can reshape a molecule and immediately test how the changes affect its function. The result was BrainCAB, a small-molecule shuttle designed to ferry medicines across the blood-brain barrier.

The mechanics are straightforward. When administered intravenously, BrainCAB binds to carbonic anhydrase IV on the cells lining brain blood vessels. That binding triggers transcytosis, the same natural transport process that viruses exploit. The shuttle and its attached cargo move across the barrier and into the brain tissue. To prove the concept worked, the team attached BrainCAB to atezolizumab, an antibody-based cancer immunotherapy used against lung and liver cancers that spread to the brain. Tests in rodents and nonhuman primates showed that BrainCAB substantially increased the amount of antibody reaching the brain—a significant result for a first proof of concept.

What makes BrainCAB potentially transformative is its simplicity. A small-molecule carrier is less likely to trigger immune rejection than protein-based shuttles. It may have minimal effect on the properties of the drug it carries. Its modular chemistry makes it easier to manufacture and adapt for different medicines. Gradinaru emphasized the platform's scope: it could rescue existing drugs that should work but cannot reach the brain, and it could enable entirely new therapeutics that researchers have not yet considered. The team believes future versions could carry multiple types of cargo simultaneously or target specific brain cell types.

But the path from laboratory to patient remains long. The findings, published in Nature Chemical Biology, are still preclinical. BrainCAB requires further refinement and testing with different drugs before its potential in human treatment can be established. Caltech has filed a patent application and licensed the technology to Receptive Bio, a startup co-founded by two of the study's lead authors. The team is now focused on further preclinical development with the longer-term goal of moving toward human clinical studies. If that work succeeds, BrainCAB could represent more than a clever workaround to a biological barrier. It could become a modular platform that finally allows medicines to reach the brain—solving a problem that has limited treatment options for neurological disease for decades.